BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX - Deutsche Boerse Ag - US1011371077 - Common Stock - Currency: EUR
BSX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. BSX has an average financial health and profitability rating. BSX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
BSX has a better Return On Assets (5.06%) than 71.19% of its industry peers.
BSX has a Return On Equity of 9.15%. This is in the better half of the industry: BSX outperforms 67.80% of its industry peers.
With a decent Return On Invested Capital value of 7.57%, BSX is doing good in the industry, outperforming 71.19% of the companies in the same industry.
BSX had an Average Return On Invested Capital over the past 3 years of 6.54%. This is below the industry average of 8.57%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.06% | ||
| ROE | 9.15% | ||
| ROIC | 7.57% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
Looking at the Profit Margin, with a value of 11.58%, BSX is in the better half of the industry, outperforming 74.58% of the companies in the same industry.
BSX's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 18.78%, BSX is doing good in the industry, outperforming 79.66% of the companies in the same industry.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
Looking at the Gross Margin, with a value of 68.65%, BSX is in the better half of the industry, outperforming 72.88% of the companies in the same industry.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.78% | ||
| PM (TTM) | 11.58% | ||
| GM | 68.65% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
The number of shares outstanding for BSX has been increased compared to 1 year ago.
BSX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BSX is higher compared to a year ago.
2.2 Solvency
BSX has an Altman-Z score of 5.92. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.92, BSX belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
BSX has a debt to FCF ratio of 3.75. This is a good value and a sign of high solvency as BSX would need 3.75 years to pay back of all of its debts.
The Debt to FCF ratio of BSX (3.75) is better than 74.58% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that BSX is not too dependend on debt financing.
BSX has a Debt to Equity ratio (0.47) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 3.75 | ||
| Altman-Z | 5.92 |
ROIC/WACC0.89
WACC8.54%
2.3 Liquidity
BSX has a Current Ratio of 1.45. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BSX (1.45) is comparable to the rest of the industry.
A Quick Ratio of 0.88 indicates that BSX may have some problems paying its short term obligations.
BSX has a worse Quick ratio (0.88) than 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.17% over the past year.
Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.35% in the last year.
Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.43% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.66% on average per year.
EPS Next Y17.26%
EPS Next 2Y15.08%
EPS Next 3Y14.28%
EPS Next 5Y12.43%
Revenue Next Year17.42%
Revenue Next 2Y14.04%
Revenue Next 3Y12.7%
Revenue Next 5Y10.66%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 37.53 indicates a quite expensive valuation of BSX.
The rest of the industry has a similar Price/Earnings ratio as BSX.
The average S&P500 Price/Earnings ratio is at 26.34. BSX is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 30.54, BSX can be considered very expensive at the moment.
BSX's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of BSX to the average of the S&P500 Index (22.19), we can say BSX is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.53 | ||
| Fwd PE | 30.54 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSX.
Based on the Price/Free Cash Flow ratio, BSX is valued a bit cheaper than 62.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.82 | ||
| EV/EBITDA | 35.05 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
BSX's earnings are expected to grow with 14.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)3.93
EPS Next 2Y15.08%
EPS Next 3Y14.28%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (6/18/2025, 7:00:00 PM)
88.2
-0.2 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.03%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap130.49B
Analysts84.21
Price Target105.28 (19.37%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.08%
Min EPS beat(2)5.6%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)7.06%
Min EPS beat(4)5.6%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.71%
EPS beat(12)11
Avg EPS beat(12)5.15%
EPS beat(16)15
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)1.51%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.04%
Revenue beat(4)4
Avg Revenue beat(4)1.92%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.02%
Revenue beat(12)10
Avg Revenue beat(12)1.79%
Revenue beat(16)12
Avg Revenue beat(16)1.49%
PT rev (1m)-0.67%
PT rev (3m)-7.39%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)0%
EPS NY rev (3m)2.01%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.53 | ||
| Fwd PE | 30.54 | ||
| P/S | 8.55 | ||
| P/FCF | 49.82 | ||
| P/OCF | 39.39 | ||
| P/B | 6.76 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.05 |
EPS(TTM)2.35
EY2.66%
EPS(NY)2.89
Fwd EY3.27%
FCF(TTM)1.77
FCFY2.01%
OCF(TTM)2.24
OCFY2.54%
SpS10.31
BVpS13.05
TBVpS-0.99
PEG (NY)2.17
PEG (5Y)3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.06% | ||
| ROE | 9.15% | ||
| ROCE | 9.4% | ||
| ROIC | 7.57% | ||
| ROICexc | 7.73% | ||
| ROICexgc | 25.4% | ||
| OM | 18.78% | ||
| PM (TTM) | 11.58% | ||
| GM | 68.65% | ||
| FCFM | 17.17% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 3.75 | ||
| Debt/EBITDA | 2.3 | ||
| Cap/Depr | 61.86% | ||
| Cap/Sales | 4.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.12% | ||
| Profit Quality | 148.25% | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 5.92 |
F-Score5
WACC8.54%
ROIC/WACC0.89
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
EPS Next Y17.26%
EPS Next 2Y15.08%
EPS Next 3Y14.28%
EPS Next 5Y12.43%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
Revenue Next Year17.42%
Revenue Next 2Y14.04%
Revenue Next 3Y12.7%
Revenue Next 5Y10.66%
EBIT growth 1Y30.17%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year32.67%
EBIT Next 3Y19.08%
EBIT Next 5Y14.7%
FCF growth 1Y151.8%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y114.76%
OCF growth 3Y22.44%
OCF growth 5Y13.34%